Tlc Biopharmaceuticals, Inc.

Taiwan Liposome Company, Ltd.

University of California

Ipsen Biopharm Limited

Merrimack Pharmaceuticals, Inc.

Sutter West Bay Hospitals

Sutter West Bay Hospital

Taiwan Lipsome Company, Ltd.

Hermes Biosciences, Inc.

Tcl Biopharmaceuticals, Inc.

Inspirmed Corp.

Ipsen Biopharma Ltd.

California Pacific Medical Center

Keelung Hong

Dmitri B Kirpotin

Yun-Long Tseng

Luke S S Guo

Daryl C Drummond

Po-Chun Chang

Sheue-Fang Shih

Demetrios P Papahadjopoulos

Weiwen Zheng

Chih-Chiang Tsai

Hong-Hui Lin

Christopher C Benz

Hao-wen Kao

John W Park

Yi-yu Lin

Yi-Yu Lin

Hao-Wen Kao

Jonathan Fang

Walter Gwathney

Mark Eamon Hayes

Luke S Guo

Wan-Ni Yu

Yung-Hsu Chan

Hong-Hul Lin

Pei Kan

Chun-yen Lai

Min-Wen Kuo

Jun-Jen Liu

ChiaHung Hung

He-Ru Chen

Ke-Ming Huang

Demetrois Papahadjopoulos

Ting-Yu Cheng

Yu-Cheng Tseng

Hsiu-Li Song

Francis C Szoka, Legal Representative

Siong-Tern Liew

Wei-Wen Zheng

Chi-Chun Lai

Jo-Hsin Tang

Wei Wen Zheng

Chiahung Hung

Luke SS Guo

Luke Ss Guo

Provided is a method for preparing a liposomal composition. The method comprises the step of contacting a liposome solution with a mild acidic agent for a limited time. The liposome solution comprises a weak acid salt encapsulated within an aqueous interior space separated from the aqueous medium by a membrane comprised of a lipid mixture containing one or more lipids and a hydrophilic polymer conjugated lipid at a molar percentage of less than 3% based on the total amount of the lipid mixture. The time for encapsulating the agent to a desired amount at a predetermined ratio to lipids is dramatically reduced even under a condition without elevating the temperature to above ambient environment.

Liposomal composition containing mild acidic active agent

The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.

Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Sustained-release anesthetic compositions and methods of preparation thereof

The present invention relates to a pharmaceutical composition comprising at least one liposome and a therapeutic agent for treating an auto-immune disease with a high therapeutic agent to lipid ratio and a high encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating an auto-immune disease using the pharmaceutical composition disclosed herein.

Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof

The present invention relates to pharmaceutical compositions comprising at least one liposome and a therapeutic agent for treating dementia with a high drug to lipid ratio and a high encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating dementia using the pharmaceutical composition disclosed herein.

Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

The present invention relates to a pharmaceutical composition comprising at least one liposome and a therapeutic agent for treating depression or anxiety, with a therapeutic agent to lipid ratio equal to or higher than about 0.15. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating depression or anxiety using the pharmaceutical composition disclosed herein.

Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof

Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Pharmaceutical composition for intraarticular delivery

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

Drug delivery system containing phospholipid and cholesterol

Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety.

Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Provided is a sustained-release triptan composition as a suitable depot formulation to carry a therapeutically effective amount of triptan for administration via subcutaneous or intramuscular injection. This sustained-release triptan composition is characterized by a high drug to phospholipid ratio and provides an improved pharmacokinetic profile in vivo. The sustained-release triptan composition is for use as a medicament in the treatment of migraine or cluster headache.

Sustained-release triptan compositions and method of use the same through subdermal route or the like

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Liposomes useful for drug delivery

Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.

Pharmaceutical compositions of hydrophobic camptothecin derivatives

Pharmaceutical compositions for intraarticular delivery

Growing community of inventors

San Francisco, CA, United States of America

Keelung Hong